Apex BioVentures to Liquidate, Unable to Complete Dynogen Acquisition Due to "Market Conditions"
Apex Bioventures, a $60,000,000 SPAC that priced its IPO in June 2007 has announced that it is terminating its planned $98,000,000 acquisition of Dynogen Pharmaceuticals.
According to the press release:
"Apex and Dynogen determined that, due to current market conditions, particularly for small capitalization public biotech companies, terminating the merger agreement was in the best interests of both companies and their respective stockholders"
This, on the heels of the spectacular, last minute blow-up of Oracle Healthcare Acquisition Corp's acquisition of Precision Therapeutics earlier this year.
Click here for the press release.
According to the press release:
"Apex and Dynogen determined that, due to current market conditions, particularly for small capitalization public biotech companies, terminating the merger agreement was in the best interests of both companies and their respective stockholders"
This, on the heels of the spectacular, last minute blow-up of Oracle Healthcare Acquisition Corp's acquisition of Precision Therapeutics earlier this year.
Click here for the press release.
Labels: Acquisitions, News
posted by SPAC Information at
8:19 AM
0 Comments:
Post a Comment
Links to this post:
Create a Link
<< Home